Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PURE BIOSCIENCE, INC.PURE · Entity 7969 | Director | May 15, 2020 | May 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PURE BIOSCIENCE, INC.
Report date May 15, 2020 · Filed May 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2030-05-15 | Direct | 100,000 |
Reported balance
After 2020-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-15 · Grant · Acquired 100,000 · Balance 100,000 F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2021 or January 15, 2021 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2022 or January 15, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2021 or January 15, 2021 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2022 or January 15, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2020 Filed Feb 10, 2020 23:54 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | SaleCommon Stock | 748,880 | $0.29 | $217,175.20 |
DisclosureSEC source: 0001209191-20-008082 · doc4.xml · nonDerivative · entry 1 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,560,540 Read SEC document |
| May 15, 2020 Filed May 19, 2020 23:05 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-20-030704 · doc4.xml · derivative · entry 1 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2021 or January 15, 2021 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2022 or January 15, 2022. Read SEC document |
| March 09, 2020 Filed Mar 12, 2020 22:05 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 1,551,724 | $0.29 | $449,999.96 |
DisclosureSEC source: 0001209191-20-018614 · doc4.xml · nonDerivative · entry 1 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,072,264 F1 · kind: This transaction was in connection with a private placement issuance by the Issuer which was approved by the Issuer's board of directors. Read SEC document |
| December 31, 2019 Filed Feb 10, 2020 23:54 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | SaleCommon Stock | 40,000 | $0.28 | $11,200.00 |
DisclosureSEC source: 0001209191-20-008082 · doc4.xml · nonDerivative · entry 2 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,520,540 Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 22:30 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 862,068 | $0.29 | $249,999.72 |
DisclosureSEC source: 0001209191-19-052412 · doc4.xml · nonDerivative · entry 1 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,309,420 Read SEC document |
| October 02, 2019 Filed Feb 6, 2020 23:02 UTC Amendment | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 862,068 | $0.29 | $249,999.72 |
DisclosureSEC source: 0001209191-20-007273 · doc4a.xml · nonDerivative · entry 1 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,309,420 F1 · kind: The previously filed Form 4 report incorrectly stated the Code as P. The transaction was in connection with a private placement issuance by the Issuer which was approved by the Issuer's board of directors and therefore the transaction should have been reported under the Code A. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 22:30 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001209191-19-052412 · doc4.xml · derivative · entry 2 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-10-01 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2020 or January 15, 2020 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2021 or January 15, 2021. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:04 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 714,285 | $0.35 | $249,999.75 |
DisclosureSEC source: 0001209191-19-029435 · doc4.xml · nonDerivative · entry 1 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,299,569 Read SEC document |
| May 09, 2019 Filed Jun 25, 2019 21:30 UTC Amendment | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 862,068 | $0.29 | $249,999.72 |
DisclosureSEC source: 0001209191-19-038988 · doc4a.xml · nonDerivative · entry 1 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,447,352 F1 · shares: The original Form 4 Report filed May 13, 2019 stated that the number of shares acquired was 714,285 at a price of $0.35 per share. This amendment reflects an amendment to the price per share. F1 · price: The original Form 4 Report filed May 13, 2019 stated that the number of shares acquired was 714,285 at a price of $0.35 per share. This amendment reflects an amendment to the price per share. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 01:30 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-19-017903 · doc4.xml · derivative · entry 1 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-03-05 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2020 or January 15, 2020 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2021 or January 15, 2021. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 22:40 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | OtherWarrant · Derivative | 213,333 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-19-012192 · doc4.xml · derivative · entry 4 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 213,333 shares Expires 2019-08-22 Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 22:40 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantWarrant · Derivative | 213,333 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-19-012192 · doc4.xml · derivative · entry 3 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,333 Underlying: Common Stock · 213,333 shares Expires 2019-08-22 F1 · kind: The reported transactions relate to an amendment of the exercise price of an outstanding warrant from $0.75 per share to $0.35 per share of Common Stock, contingent upon the Reporting Person immediately exercising the Warrant. As a result of this amendment, the outstanding warrant was deemed canceled and a replacement warrant was issued for the same number of shares of Common Stock, but with the reduced exercise price. The outstanding warrant was originally issued on August 2014. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 22:40 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | Disposition to issuerWarrant · Derivative | 213,333 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001209191-19-012192 · doc4.xml · derivative · entry 2 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 213,333 shares Expires 2019-08-22 F1 · kind: The reported transactions relate to an amendment of the exercise price of an outstanding warrant from $0.75 per share to $0.35 per share of Common Stock, contingent upon the Reporting Person immediately exercising the Warrant. As a result of this amendment, the outstanding warrant was deemed canceled and a replacement warrant was issued for the same number of shares of Common Stock, but with the reduced exercise price. The outstanding warrant was originally issued on August 2014. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 22:40 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | OtherCommon Stock | 213,333 | $0.35 | $74,666.55 |
DisclosureSEC source: 0001209191-19-012192 · doc4.xml · nonDerivative · entry 1 Okuno Dale · CIK 0001608989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,585,284 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.